HilleVax expanded its pipeline in January 2024 by in-licensing HIL-216.00, a hexavalent Virus-Like Particle (VLP) norovirus vaccine candidate. This agreement was made with Chengdu Kanghua Biological Products Co., Ltd., granting HilleVax rights outside Greater China. The in-licensing involved an upfront payment of $15 million.
This strategic move signaled HilleVax's continued commitment to addressing the global burden of norovirus infection. HIL-216.00 is a VLP-based vaccine candidate, aligning with the company's core technological approach. The expansion aimed to bolster HilleVax's position in the norovirus vaccine development space.
The addition of HIL-216.00 to the pipeline provided a new development candidate following the company's initial focus on HIL-214.00. This diversification within the norovirus segment was intended to strengthen HilleVax's long-term potential in vaccine development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.